Clinical Trials Browser

NCT00664898 2022-12-12

A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Completed

18 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00079716 2014-12-18

Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma

Phase 1 Completed

44 enrolled

LymphoidPlasma cell

Blood Coagulation Disorders, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

NCT00525447 2014-10-09

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

Phase 1 Completed

36 enrolled

LymphoidPlasma cell

Blood Coagulation Disorders, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Paraproteinemias, Vascular Diseases, Hemostatic Disorders